Document:

Form of Warrant Series D Convertible Preferred Stock

 Exhibit 10.14 
 The following warrants were issued to Medtronic, Inc., using the Form below: 
  

						
	 Date
	  	Number of Series D
Convertible Preferred
Shares Issued	  	Exercise Price
	 05/15/04
	  	4,404	  	$	1.263
	 08/14/04
	  	4,300	  	$	1.263
	 11/14/04
	  	4,564	  	$	1.263
	 02/14/05
	  	5,113	  	$	1.263
	 05/15/05
	  	5,115	  	$	1.263
	 08/14/05
	  	3,986	  	$	1.263
	 11/14/05
	  	3,858	  	$	1.263
	 02/14/06
	  	3,801	  	$	1.263
	 05/15/06
	  	3,417	  	$	1.263
	 08/14/06
	  	3,533	  	$	1.263
	 07/18/06
	  	25,255	  	$	1.263
	 11/14/06
	  	6,208	  	$	1.263
	 02/14/07
	  	7,466	  	$	1.263
	 05/15/07
	  	9,300	  	$	1.263
	 08/14/07
	  	11,514	  	$	1.263
	 11/14/07
	  	12,608	  	$	1.263
	 02/14/08
	  	14,589	  	$	1.263

 THIS WARRANT, AND THE SHARES OF SERIES D PREFERRED STOCK ISSUABLE UPON EXERCISE HEREOF, HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE “SECURITIES ACT”) OR ANY APPLICABLE FOREIGN OR STATE SECURITIES LAWS. THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION UNDER SUCH ACT OR LAWS UNLESS OFFERRED, SOLD OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT OR LAWS. 
 WARRANT 
 To Purchase Shares of Series D Convertible Preferred Stock of

 TISSUELINK MEDICAL, INC. 
 [Date] 
 TissueLink Medical, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies
that Medtronic, Inc. a Minnesota corporation, or its registered assigns (the “Holder”) is entitled, subject to the terms set forth below, upon exercise of this Warrant to purchase from the Company such number of shares of Series D
Convertible Preferred Stock, $.01 par value per share, of the Company (“Series D Preferred Stock”) specified in Section 2(b) below at the exercise price per share specified in Section 2(a) below (as adjusted pursuant to
the terms of this Warrant). The shares of Series D Preferred Stock issuable upon exercise of this Warrant, as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant
Shares.” 
 This Warrant is further subject to the following provisions, terms and conditions: 
 1. Term; Limitation Upon Exercise. 
 (a) Except as set forth in Section 1(b) below, this Warrant may be exercised by the Holder, in whole or in part, in the manner described in Section 3 hereof at any time before the close of business on the later of: (i) the
date ten (10) years after the date hereof; or (ii) the date thirty (30) calendar days after delivery of the “Expiration Notice” (as defined below) to the Holder. “Expiration Notice” shall mean written notice
from the Company specifying the termination date of this warrant and delivered to the Holder not earlier than the date one hundred eighteen (118) calendar months after the date hereof. 
 (b) Except upon or in connection with the liquidation, dissolution or winding-up of the Company (a “Liquidation Event”), the Holder may
exercise this Warrant only to the extent that such Holder, together with its affiliates, immediately after such exercise, would own voting shares or power representing no more than nineteen and one-half percent (19.9%) of the total outstanding
voting shares or power of the Company. No such limitation shall apply to any exercise by the Holder upon or in connection with a Liquidation Event. 

 2. Warrant Shares and Exercise Price. 
 (a) Exercise Price. The per share warrant exercise price (the “Exercise Price”) shall equal     , subject to
adjustment thereafter as provided herein. 
 (b) Number of Warrant Shares. The number of shares which may be purchased upon exercise
of this Warrant shall equal , subject to adjustment as provided herein. 
 3. Manner of Exercise. This Warrant may be exercised by the
Holder, in whole or in part (but not as to any fraction of a share of Series D Preferred Stock), by surrendering this Warrant, with the Exercise Form attached hereto as Exhibit A filled in and duly executed by such Holder or by such
Holder’s duly authorized attorney, to the Company at its principal office accompanied by payment of the aggregate exercise price therefore (equal to the Exercise Price multiplied by the number of shares as to which the Warrant is being
exercised). The Exercise Price may be paid in the form of a check or wire transfer of immediately available funds. 
 4. Effective Date of
Exercise. Each exercise of this Warrant shall be deemed effective as of the close of business on the day on which this Warrant is surrendered to the Company as provided in Section 3 above. At such time, the person or persons in whose name
or names any certificates for Warrant Shares shall be issuable upon such exercise shall be deemed to have become the holder or holders of record of the Warrant Shares represented by such certificates. Within 10 days after the exercise of this
Warrant in full or in part, the Company will, at its expense, cause to be issued in the name of and delivered to the Holder or such other person as the Holder may (upon payment by such Holder of any applicable transfer taxes) direct: (i) a
certificate or certificates for the number of full Warrant Shares to which such Holder is entitled upon such exercise, and (ii) unless this Warrant has expired, a new Warrant or Warrants (dated the date hereof and in form identical hereto)
representing the right to purchase the remaining number of shares of Series D Preferred Stock, if any, with respect to which this Warrant has not then been exercised. 
 5. Protection Against Dilution. 
 (a) Adjustment for Stock Splits, Dividends and Combinations.
If the Company, at any time after the date of this Warrant, subdivides, declares a dividend payable in, or combines the outstanding shares of Series D Preferred Stock then (i) the number of shares of Series D Preferred Stock for which this
Warrant may be exercised as of immediately prior to the subdivision, combination or record date for such dividend payable in Series D Preferred Stock shall forthwith be proportionately decreased, in the case of combination, or increased, in the case
of subdivision or dividend payable in Series D Preferred Stock, and (ii) the Exercise Price in effect immediately prior to the subdivision, combination or record date for such dividend payable in Series D Preferred Stock shall forthwith be
proportionately increased, in the case of combination, or decreased, in the case of subdivision or dividend payable in Series D Preferred Stock. 
 (b) Adjustment for Other Dividends and Distributions. If the Company, at any time after the date of this Warrant, distributes to holders of Series D Preferred Stock any assets or debt securities or any rights or warrants to purchase
debt securities, assets or other securities (including Series D Preferred Stock), the Exercise Price shall be adjusted in accordance with the formula: 
  

							
	 El
	 	=	 	E x [(O x M) – F]	 	
		 		 	O x M	 	

  

 -2- 

					
	 where:
	  		  	
			
		  	El =	  	the adjusted Exercise Price.
			
		  	E =	  	the Exercise Price prior to adjustment pursuant to this subsection.
			
		  	M =	  	the fair market value per share of Series D Preferred Stock before the record date mentioned below, as determined in good faith by the Company’s Board of Directors.
			
		  	O =	  	the number of shares of Series D Preferred Stock outstanding on the record date mentioned below.
			
		  	F =	  	the fair market value on the record date of the aggregate of all assets, securities, rights or warrants distributed, as determined in good faith by the Company’s Board of
Directors.

 The adjustment shall be made successively whenever any such distribution is made and shall become
effective immediately after the record date for the determination of stockholders entitled to receive the distribution. Upon each adjustment of the Exercise Price, the Holder shall be entitled to purchase, at the Exercise Price resulting from such
adjustment, the number of shares that is equal to the quotient of (i) the Exercise Price immediately prior to such adjustment multiplied by the number of shares purchasable pursuant hereto immediately prior to such adjustment; divided by
(ii) the Exercise Price. 
 (c) Adjustment for Reorganizations, Mergers, Etc. If any capital reorganization or reclassification
of the capital stock of the Company, or share exchange, combination, consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets to another corporation shall be effected in such a way that
holders of Series D Preferred Stock shall be entitled to receive stock, securities or assets with respect to or in exchange for Series D Preferred Stock, then, as a condition of such reorganization, reclassification, share exchange, combination,
consolidation, merger or sale, lawful and adequate provision shall be made whereby the Holder shall thereafter have the right to receive upon exercise of this Warrant, upon the basis and upon the terms and conditions specified in this Warrant and in
lieu of the shares of the Series D Preferred Stock of the Company into which this Warrant could be exercisable, such shares of stock, securities or assets as may be issued or payable with respect to or in exchange for a number of outstanding shares
of such Series D Preferred Stock equal to the maximum number of shares of such stock issuable upon exercise of this Warrant, and in any such case appropriate provisions shall be made with respect to the rights and interests of Holder to the end that
the provisions hereof (including without limitation provisions for adjustments of the Exercise Price and of the number 

  

 -3- 

 
of shares purchasable upon exercise of this Warrant) shall thereafter be applicable, as nearly as may be, in relation to any shares of stock, securities or
assets thereafter deliverable upon the exercise hereof. The Company shall not effect any such share exchange, combination, consolidation, merger or sale, unless prior to the consummation thereof the successor corporation (if other than the Company)
resulting from such share exchange, combination, consolidation or merger or the corporation purchasing such assets shall assume by written instrument executed and mailed to the Holder, at the last address of such Holder appearing on the books of the
Company, the obligation to deliver to such Holder such shares of stock, securities or assets that, in accordance with the foregoing provisions, such Holder may thereafter be entitled to receive upon exercise of this Warrant. 
 (d) Successive Adjustments and Notice. The above provisions of this Section 5 shall similarly apply to successive stock splits, combinations,
dividends, reorganizations, reclassifications, consolidations, mergers or sales. The Company shall deliver written notice of each such event, and of each such adjustment to the Exercise Price resulting from such proposed event, to the Holder not
less than twenty (20) days prior to such event. If any event occurs of the type contemplated by the adjustment provisions herein, but which is not expressly provided for by such provisions, the Company will deliver notice of such event as
provided above and the Company will make an appropriate adjustment in the Exercise Price and the number and type of shares acquirable upon exercise of this Warrant so that the rights of the Holder shall be neither enhanced nor diminished as a result
of such event. 
 (e) Issuance of Convertible Securities. If the Company in any manner issues or sells any options, warrants or rights
to subscribe for or to purchase Series D Preferred Stock, or securities convertible into shares of Series D Preferred Stock (such options, warrants, rights or securities being herein called “Series D Convertible Securities”), the
Company shall be deemed to have issued the maximum number of shares of Series D Preferred Stock issuable upon the exercise or conversion of such Series D Convertible Securities for consideration equal to the amount of consideration, if any, received
by the Company upon issuance of such Series D Convertible Securities plus the minimum aggregate amount of consideration payable to the Company upon exercise or conversion of such Series D Convertible Securities. 
 (f) Price Protection. If the Company issues or sells, or is deemed to have issued or sold, Series D Preferred Stock for consideration per share
less than the Exercise Price in effect at the time of such issuance, then effective immediately upon such issuance the Exercise Price shall be reduced to equal the amount of such consideration per share. Notwithstanding the foregoing, the adjustment
provided for in this Section 5(f) shall not apply to the issuance of Company capital stock upon exercise of options granted prior to the date hereof pursuant to employee benefit plans approved by the Company’s Board of Directors.

 6. No Voting Rights. This Warrant shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company
unless and until exercised pursuant to the provisions hereof. 
 7. Transfer or Exchange without Registration. In the event the Holder
desires to transfer this Warrant, the Holder shall provide the Company written notice describing the manner of such transfer and an opinion of counsel that the proposed transfer may be effected without registration under the Securities Act or
applicable state securities registration laws, whereupon the Holder shall be 

  

 -4- 

 
entitled to transfer this Warrant in accordance with such notice. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and, in the case of any such loss, theft, or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form an amount to the Company, or, in the case of any such mutilation, upon
surrender of this Warrant, the Company, at its expense, will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
 Notwithstanding anything herein to the contrary, this Warrant may not be transferred by the Holder hereof except to a direct or indirect subsidiary of Medtronic, Inc., a Minnesota corporation (which shall specifically exclude the Medtronic
Foundation). Further, the Holder, by acceptance hereof, agrees not to sell or transfer any Warrant Shares (or the shares of Common Stock issuable upon conversion thereof) for at least thirty-two (32) days after the exercise of this Warrant
which resulted in the issuance of such Warrant Shares. 
 8. Covenants of the Company. The Company covenants and agrees that all
shares that may be issued upon exercise of this Warrant will, upon issuance, be duly authorized and issued, fully paid, nonassessable and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and
agrees that the Company has and will at all times have authorized, and reserved for the purpose of issuance upon exercise hereof, a sufficient number of shares of its Series D Preferred Stock to provide for the exercise of this Warrant. 

9. Certain Notices. The Holder shall be entitled to receive from the Company immediately upon declaration thereof and at least 20 days prior to
the record date for determination of shareholders entitled thereto or to vote thereon (or, if no record date is set, prior to the event), written notice of any event that could require an adjustment pursuant to Section 5 hereof or of the
dissolution, liquidation or winding up of the Company. All notices under this Warrant shall be in writing and shall be delivered personally or by telecopy (receipt confirmed) to such party (or, in the case of an entity, to an executive officer of
such party) or shall be sent by a reputable express delivery service or by certified mail, postage prepaid with return receipt requested, addressed as follows: 
 if to the Holder, to: 
 Medtronic, Inc. 
 World Headquarters 
 710 Medtronic Parkway, N.E. 
 Minneapolis, MN 55432-5604 
 Attention:
General Counsel 
 Fax: (763) 572-5459 
  

 -5- 

 With a copy to: 
 Medtronic, Inc. 
 World Headquarters 
 710 Medtronic Parkway, N.E. 
 Minneapolis, MN 55432-5604 
 Attention: Vice President and Chief Development Officer 
 Fax: (763) 505-2542 
 if to the Company to: 
 TissueLink Medical, Inc. 
 One Washington
Center 
 Suite 400 
 Dover, NH
03820 
 Attn: Joseph Army, VP & CFO 
 Fax: (603) 742-1488 
 with a copy to: 
 Ropes & Gray 
 One International Place 
 Boston, MA 02110 
 Attention: Michael F.
Sexton 
 Fax: (617) 951-7050 
 Any party may change the above-specified recipient and/or mailing address by notice to all other parties given in the manner herein prescribed. All notices shall be deemed given on the day when actually delivered as provided above (if
delivered personally or by telecopy) or on the day shown on the return receipt (if delivered by mail or delivery service). 
 10.
Registration Rights. The Holder of this Warrant and any Warrant Shares are entitled to the rights and benefits of all of the terms, provisions and conditions of that certain that certain Investors’ Rights Agreement dated August 9,
1999 by and among the Company, Holder and certain other investors and all other registration rights granted to any other holder of Series D Preferred Stock. 
 11. Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Minnesota without reference to the choice of law principles thereof. Without limiting the rights of
the parties to pursue in any appropriate jurisdiction their respective rights with respect to any judgment obtained in respect hereof, the parties hereby irrevocably consent to the exclusive jurisdiction and venue of the courts of the State of
Minnesota or any United States court of competent jurisdiction situated therein to adjudicate any legal action commenced in respect of this Warrant and waive any objections either may have at any time to such jurisdiction and venue. The parties
agree to the personal jurisdiction of such courts and agree that service of process may be made pursuant to notice sent in accordance with Section 10. 
  

 -6- 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by its authorized officer and dated
as of the date stated above. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	  

		
	Its:	 	  

  

 -7- 

 Exhibit A 
  

			
	 NOTICE OF EXERCISE OF WARRANT —
	 	To Be Executed by the Registered Holder in Order to Exercise the Warrant

 The undersigned hereby irrevocably elects to exercise the attached Warrant to purchase, for cash
pursuant to Section 2 thereof,                                 shares of
Series D Preferred Stock issuable upon the exercise of such Warrant. The undersigned requests that certificates for such shares be issued in the name of
                                        .
If this Warrant is not fully exercised, the undersigned requests that a new Warrant to purchase the balance of shares remaining purchasable hereunder be issued in the name of
                                        .

  

					
	Date:                         , 200    
	 	MEDTRONIC, INC.
			
		 	By:	 	  

			
		 	Its:	 	  

		
		 	World Headquarters
		 	710 Medtronic Parkway, N.E.
		 	Minneapolis, MN 55432-5604
		
		 	  

		 	[tax identification number]

  

 -8-Form of Warrant Series D Convertible Preferred Stock

 Exhibit 10.15 
 The following warrants were issued using the Form below: 
  

								
	 Entity
	  	Date	  	Number of Series D
Convertible Preferred
Shares Issued	  	Exercise Price
	 Horizon Technology Funding Company II LLC
	  	05/24/2005	  	395,883	  	$	1.263
	 Horizon Technology Funding Company III LLC
	  	05/24/2005	  	395,883	  	$	1.263

 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO
SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED,
(iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT. 
 TISSUELINK MEDICAL, INC 
 WARRANT TO PURCHASE UP TO
                     SHARES OF SERIES D 
 CONVERTIBLE PREFERRED STOCK 
 THIS CERTIFIES THAT, for value received, [HORIZON TECHNOLOGY FUNDING COMPANY II LLC or HORIZON
TECHNOLOGY FUNDING COMPANY III LLC] and its permitted assignees are entitled to subscribe for and purchase up to              shares (as determined in accordance with the terms of the next
paragraph) of the fully paid and nonassessable Series D Convertible Preferred Stock (as adjusted pursuant to Section 4 hereof, the “Shares”) of TISSUELINK MEDICAL, INC., a Delaware corporation (the “Company”), at the price
of $1.263 per share (such price and such other price as shall result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms
and conditions hereinafter set forth. As used herein, (a) the term “Series Preferred” shall mean the Company’s presently authorized Series D Convertible Preferred Stock, and any stock into or for which such Series D Convertible
Preferred Stock may hereafter be converted or exchanged, and after the automatic conversion of the Series D Convertible Preferred Stock to Common Stock shall mean the Company’s Common Stock, (b) the term “Date of Grant” shall
mean May     , 2005, and (c) the term “Other Warrants” shall mean any other warrants issued by the Company in connection with the transaction contemplated by the Loan Agreement (as defined below) with
respect to which this Warrant was issued, and any warrant issued upon transfer or partial exercise of or in lieu of this Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly
requires otherwise. 
 The number of shares for which this Warrant is exercisable shall be equal to
             plus, the sum of (a) if and only if, the Company shall have borrowed Loan B (as defined in that certain Venture Loan and Security Agreement by and between the
Company and Horizon Technology Funding Company LLC (“Horizon”) dated on or about the Date of Grant (the “Loan Agreement”)),              shares plus (b) if
and only if, the Company shall have borrowed Loan C (as defined in the Loan Agreement),              shares. 

 1. Term. The purchase right represented by this Warrant is exercisable, in whole or in part, at
any time and from time to time from the Date of Grant through ten (10) years after the Date of Grant. 
 2. Method of Exercise;
Payment; Issuance of New Warrant. Subject to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by
(a) the surrender of this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-I duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank
check, or by wire transfer to an account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b) if in connection with a
registered public offering of the Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company together with notice of
arrangements reasonably satisfactory to the Company for payment to the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of shares to be sold by the holder in such public offering of an amount equal to the
then applicable Warrant Price per share multiplied by the number of Shares then being purchased (provided, however, that this clause (b) shall not be deemed to entitle the holder hereof to sell any Shares in any public offering of the
Company’s securities); or (c) exercise of the “net issuance” right provided for in Section 10.2 hereof. The person or persons in whose name(s) any certificate(s) representing shares of Series Preferred shall be issuable upon
exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately
prior to the close of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be delivered to the holder
hereof as soon as possible and in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to which this
Warrant shall not then have been exercised shall also be issued to the holder hereof as soon as possible and in any event within such thirty-day period; provided, however, at such time as the Company is subject to the reporting requirements of the
Securities Exchange Act of 1934, as amended, if requested by the holder of this Warrant, the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker or other person (as
directed by the holder exercising this Warrant) within the time period required to settle any trade made by the holder after exercise of this Warrant. 
 3. Stock Fully Paid: Reservation of Shares. All Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully
paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the issue thereof. During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have
authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this Warrant, a sufficient number of shares of its Series Preferred to provide for the exercise of the rights represented by this Warrant and a
sufficient number of shares of its Common Stock to provide for the conversion of the Series Preferred into Common Stock. 
  

 -2- 

 4. Adjustment of Warrant Price and Number of Shares. The number and kind of securities purchasable
upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
 (a) Reclassification or Merger. In case of any reclassification or change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value,
or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another corporation (other than a merger with another corporation in which the Company is the acquiring and the
surviving corporation and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or
such successor or purchasing corporation, as the case may be, shall duly execute and deliver to the holder of this Warrant a new Warrant (in form and substance satisfactory to the holder of this Warrant), so that the holder of this Warrant shall
have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Series Preferred theretofore issuable upon
exercise of this Warrant, (i) the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number of shares of Series Preferred then purchasable
under this Warrant, or (ii) in the case of such a merger or sale in which the consideration paid consists all or in part of assets other than securities of the successor or purchasing corporation, at the option of the holder of this Warrant,
the securities of the successor or purchasing corporation having a value at the time of the transaction equivalent to the value of the Series Preferred purchasable upon exercise of this Warrant at the time of the transaction. Any new Warrant shall
provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this Section 4(a) shall similarly apply to successive reclassifications, changes, mergers
and sales. 
 (b) Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and
unexpired shall subdivide or combine its outstanding shares of Series Preferred, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the
Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination. 
 (c) Stock Dividends and Other Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay a dividend with respect to Series Preferred payable in Series
Preferred, then the Warrant Price shall be adjusted, from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to
such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Series Preferred outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total
number of shares of Series Preferred outstanding immediately after such dividend or distribution; or (ii) make any other distribution with respect to Series Preferred (except any distribution specifically provided for in Sections 4(a) and
4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant shall receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the

  

 -3- 

 
Series Preferred (or Common Stock issuable upon conversion thereof) as of the record date fixed for the determination of the shareholders of the Company
entitled to receive such dividend or distribution. 
 (d) Adjustment of Number of Shares. Upon each adjustment in the Warrant Price,
the number of Shares of Series Preferred purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a
fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter. 
 (e) Antidilution Rights. The other antidilution rights applicable to the Shares of Series Preferred purchasable hereunder are set forth in the
Company’s Certificate of Incorporation, as amended through the Date of Grant (the “Charter”). Any restatement, amendment, modification or waiver of such antidilution rights that is in any manner adverse to the holder hereof (other
than a restatement, amendment, modification or waiver that applies on the same terms to all holders of Series Preferred) will not be effective against the holder hereof without such holder’s prior written consent. The Company shall promptly
provide the holder hereof with any restatement, amendment, modification or waiver of such antidilution rights in the Charter promptly after the same has been made. 
 (f) Conversion of Series Preferred. In the event all outstanding shares of Series Preferred are converted into shares of Common Stock pursuant to the provisions of the Charter, this Warrant shall thereafter
entitle the holder hereof to purchase (at the aggregate Warrant Price in effect immediately prior to the time of such conversion) that number of shares of Common Stock into which the number of shares of Series Preferred for which this Warrant is
exercisable would have converted had such shares of Series Preferred been issued immediately prior to the conversion. 
 5. Notice of
Adjustments. Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted pursuant to Section 4 hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable
detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall
cause copies of such certificate to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant. In addition, whenever the conversion price or conversion ratio of the Series Preferred
shall be adjusted in accordance with the Charter, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which
such adjustment was calculated, and the conversion price or ratio of the Series Preferred after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 13 hereof, by first class mail,
postage prepaid) to the holder of this Warrant. 
 6. Fractional Shares. No fractional shares of Series Preferred will be issued in
connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on the fair market value of the Series Preferred on the date of exercise as reasonably determined in good faith by the
Company’s Board of Directors. 
  

 -4- 

 7. Compliance with Act: Disposition of Warrant or Shares of Series Preferred. 
 (a) Compliance with Act. The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred to be
issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred to be issued upon
exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not result in a violation of the Securities Act of 1933, as amended (the “Act”) or applicable state securities laws. Upon exercise of
this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the shares of Series Preferred
so purchased (and any shares of Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be
reasonably requested by the Company. This Warrant and all shares of Series Preferred issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the Act and any applicable state
securities laws) shall be stamped or imprinted with a legend in substantially the following form: 
 “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE,
REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT
UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.” 
 Said legend shall be removed by the Company, upon the request of a
holder, at such time as the restrictions on the transfer of the applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant
as follows: 
 (1) The holder is aware of the Company’s business affairs and financial condition, and has acquired information about the
Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any
“distribution” thereof in violation of the Act. 
 (2) The holder understands that this Warrant has not been registered under the
Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent as expressed herein. 
  

 -5- 

 (3) The holder further understands that this Warrant must be held indefinitely unless subsequently
registered under the Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act.

 (4) The holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Act.

 (b) Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any shares of Series
Preferred acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written
opinion of such holder’s counsel, or other evidence, if reasonably satisfactory to the Company, to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or
any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred to be sold or
otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company,
as promptly as practicable but no later than fifteen (15) days after receipt of the written notice, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such shares of Series Preferred or Common Stock, all
in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 7(b) that the opinion of counsel for the holder or other evidence is not reasonably satisfactory to the Company, the
Company shall so notify the holder promptly with details thereof after such determination has been made. Notwithstanding the foregoing, this Warrant or such shares of Series Preferred or Common Stock may, as to such federal laws, be offered, sold or
otherwise disposed of in accordance with Rule 144 or I 44A under the Act, provided that the Company shall have been furnished with such information as the Company may reasonably request to provide a reasonable assurance that the provisions of Rule
144 or 144A have been satisfied. Each certificate representing this Warrant or the shares of Series Preferred thus transferred (except a transfer pursuant to Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability
in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent
in connection with such restrictions. 
 (c) Applicability of Restrictions. Neither any restrictions of any legend described in this
Warrant nor the requirements of Section 7(b) above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Series Preferred or Common Stock obtainable upon exercise thereof) or any part hereof (i) to a
partner of the holder if the holder is a partnership or to a member of the holder if the holder is a limited liability company, (ii) to a partnership of which the holder is a partner or to a limited liability company of which the holder is a
member, or (iii) to any affiliate of the holder if the holder is a corporation; provided, however, that the transferor shall give prior notice to the Company of such transfer and in any such transfer, if applicable, the transferee
shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. 
  

 -6- 

 (d) Subsequent Transfers. As a condition to the effectiveness of any transfer of this Warrant, the
transferee shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original holder hereof. 
 8. Rights as Shareholders: Information. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder of Series Preferred or any other securities of the Company which may at any time be
issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a shareholder of the Company or any right to vote for the election of
directors or upon any matter submitted to shareholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Shares purchasable upon
the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing, the Company will transmit to the holder of this Warrant such information, documents and reports as are generally distributed to the holders of any
class or series of the securities of the Company concurrently with the distribution thereof to the shareholders. 
 9. Registration
Rights. Pursuant to a separate Joinder Agreement dated on or about the Date of Grant executed by the Company and the holders of the Date of Grant, the Company grants registration rights to the holder of this Warrant for any Common Stock of the
Company obtained upon conversion of the Series Preferred, comparable to the registration rights granted to the investors in that certain Investors’ Rights Agreement dated as of January 31, 2003, (the “Investors’ Rights
Agreement”), with the following exceptions and clarifications, all as set forth in and subject to the above-referenced Joinder Agreement: 
 (1) The holder will not have the right to demand registration, but can otherwise participate in any registration demanded by others in accordance with the terms of the Investors’ Rights Agreement. 
 (2) The holder will be subject to the same provisions regarding indemnification as contained in the Investors’ Rights Agreement. 
 (3) The registration rights are freely assignable by the holder of this Warrant in connection with a permitted transfer of this Warrant or the Shares.

 10. Additional Rights. 
 10.1 Acquisition Transactions. The Company shall provide the holder of this Warrant with at least twenty (20) days’ written notice prior to closing thereof of the terms and conditions of any of the following transactions
(to the extent the Company has notice thereof): (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the Company’s property or business, or (ii) its merger into or consolidation with any other
corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of.

  

 -7- 

 10.2 Right to Convert Warrant into Stock: Net Issuance. 
 (a) Right to Convert. In addition to and without limiting the rights of the holder under the terms of this Warrant, the holder shall have the right
to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of Series Preferred as provided in this Section 10.2 at any time or from time to time during the term of this Warrant. Upon exercise of the Conversion
Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the holder (without payment by the holder of any exercise price or any cash or other consideration)
that number of shares of fully paid and nonassessable Series Preferred as is determined according to the following formula: 
  

			
	X =	  	B – A
		  	    Y

  

			
	Where: X =	  	the number of shares of Series Preferred that shall be issued to holder
		
	Y =	  	the fair market value of one share of Series Preferred
		
	A =	  	the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (i.e., the number of Converted Warrant Shares
multiplied by the Warrant Price)
		
	B =	  	the aggregate fair market value of the specified number of Converted Warrant Shares (i.e., the number of Converted Warrant Shares multiplied by the fair market value of one Converted
Warrant Share)

 No fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number
of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value of the resulting fractional share on the Conversion Date
(as hereinafter defined). For purposes of Section 10 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the exercise of this Warrant. 
 (b) Method of Exercise. The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of the
Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which
are being surrendered (referred to in Section 10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid
written statement, or on such later date as is specified therein (the “Conversion Date”), and, at the election of the holder hereof, may be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a
public offering pursuant to a Registration Statement under the Act (a “Public Offering”). Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares
remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30) days following the Conversion Date. 
  

 -8- 

 (c) Determination of Fair Market Value. For purposes of this Section 10.2, “fair market
value” of a share of Series Preferred (or Common Stock if the Series Preferred has been automatically converted into Common Stock) as of a particular date (the “Determination Date”) shall mean: 
 (i) If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s Registration Statement
relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect to such
offering. 
 (ii) If the Conversion Right is not exercised in connection with and contingent upon a Public Offering, then as follows:

 (A) If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the average of the closing prices
of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the number
of shares of Common Stock into which each share of Series Preferred is then convertible; 
 (B) If traded on the Nasdaq Stock Market or other
over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of the closing bid prices of the Common Stock over the five trading days immediately prior to the Determination Date, and the fair market value of
the Series Preferred shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred is then convertible; and 
 (C) If there is no public market for the Common Stock, then fair market value shall be determined by the Board of Directors of the Company in good faith.

 In making a determination under clauses (A) or (B) above, if on the Determination Date, five trading days had not passed since the closing of
the Company’s initial public offering of its Common Stock (“IPO”) effected pursuant to a Registration Statement on Form S-I (or its successor) filed under the Act, then the fair market value of the Common Stock shall be the average
closing prices or closing bid prices, as applicable, for the shorter period beginning on and including the date of the IPO and ending on the trading day prior to the Determination Date (or if such period includes only one trading day the closing
price or closing bid price, as applicable, for such trading day). If closing prices or closing bid prices are no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported
by such securities exchange or other trading system at 4:00 p.m. New York City time on the applicable trading day. 
 10.3 Exercise Prior
to Expiration. To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if the fair market value of one share of the Series Preferred is greater than the Warrant Price then in effect, this Warrant shall
be deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered) immediately before its expiration. For 

  

 -9- 

 
purposes of such automatic exercise, the fair market value of one share of the Series Preferred upon such expiration shall be determined pursuant to
Section 10.2(c). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any, the holder hereof
is to receive by reason of such automatic exercise. 
 11. Representations and Warranties. The Company represents and warrants to the
holder of this Warrant as follows: 
 (a) This Warrant has been duly authorized and executed by the Company and is a valid and binding
obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance,
injunctive relief and other equitable remedies. 
 (b) The Shares have been duly authorized and reserved for issuance by the Company and,
when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable and free from preemptive rights. 
 (c)
The rights, preferences, privileges and restrictions granted to or imposed upon the Series Preferred and the holders thereof are as set forth in the Charter, and on the Date of Grant, each share of the Series Preferred represented by this Warrant is
convertible into one share of Common Stock. 
 (d) The shares of Common Stock issuable upon conversion of the Shares have been duly
authorized and reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and nonassessable. 
 (e) The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the terms hereof will not be, inconsistent with the Company’s Charter or
by-laws, do not and will not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or contravene any provision of, or constitute a default under, any indenture,
mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the registration or filing with or the taking of any action in respect of or by, any
Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings will be effected by the time required thereby, and except for any required
consents, approvals and waivers that have been obtained. 
 (f) There are no actions, suits, audits, investigations or proceedings pending
or, to the knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform
its obligations under this Warrant. 
 (g) The number of shares of Common Stock of the Company outstanding on the date hereof, on a frilly
diluted basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding options and warrants), does not exceed 55,000,000 shares. 
  

 -10- 

 12. Modification and Waiver. This Warrant and any provision hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
 13.
Notices. Any notice, request, communication or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each
such holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant. 
 14. Binding Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets, and
all of the obligations of the Company relating to the Series Preferred issuable upon the exercise or conversion of this Warrant shall survive the exercise, conversion and termination of this Warrant and all of the covenants and agreements of the
Company shall inure to the benefit of the successors and assigns of the holder hereof. 
 15. Lost Warrants or Stock Certificates. The
Company covenants to the holder hereof that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or
destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock
certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 
 16. Descriptive
Headings. The descriptive headings of the various Sections of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to
which party drafted this Warrant. 
 17. Governing Law. This Warrant shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of Delaware. 
 18. Survival of Representations, Warranties and
Agreements. All representations and warranties of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights
hereunder. All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative. 
 19. Remedies. In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case
of a breach by a holder), may proceed to protect and enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific
performance of any such covenant or agreement contained in this Warrant. 
  

 -11- 

 20. No Impairment of Rights. The Company will not, by amendment of its Charter or through any
other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the holder of this Warrant against impairment. 
 21. Severability. The invalidity or
unenforceability of any provision of this Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and
effect. 
 22. Recovery of Litigation Costs. If any legal action or other proceeding is brought for the enforcement of this Warrant,
or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover reasonable attorneys’ fees and other
costs incurred in that action or proceeding, in addition to any other relief to which it or they may be entitled. 
 23. Entire Agreement;
Modification. This Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether
oral or written, with respect to such subject matter. 
  

 -12- 

 The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant specified
above. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

			
		
	Address:	 	 One Washington Center, Suite 400
 Dover, New Hampshire
03820

  

 -13- 

 EXHIBIT A-1 
 NOTICE OF EXERCISE 
 To: TISSUELINK MEDICAL, INC. (the “Company”) 
 1. The undersigned hereby: 
 elects to
purchase          shares of [Series Preferred Stock] [Common Stock] of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in
full, or 
 elects to exercise its net issuance rights pursuant to Section 10.2 of the attached Warrant with respect to
         Shares of [Series Preferred Stock] [Common Stock]. 
 2. Please issue a certificate
or certificates representing          shares in the name of the undersigned or in such other name or names as are specified below: 
  

			
		 	  

		 	(Name)
		
		 	  

		
		 	  

		 	(Address)

 3. The undersigned represents that the aforesaid shares are being acquired for the account of the
undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable
securities laws. 
  

	
	  

	(Signature)

  

			
	  
	 	
	(Date)	 	

 EXHIBIT A-2 
 NOTICE OF EXERCISE 
 To: TISSUELINK MEDICAL, INC. (the “Company”) 
 1. Contingent upon and effective immediately prior to the closing (the “Closing”) of the Company’s public offering contemplated by the
Registration Statement on Form S    , filed                     , 200    , the
undersigned hereby: 
 elects to purchase              shares of [Series
Preferred Stock] [Common Stock] of the Company (or such lesser number of shares as may be sold on behalf of the undersigned at the Closing) pursuant to the terms of the attached Warrant, or 
 elects to exercise its net issuance rights pursuant to Section 10.2 of the attached Warrant with respect to
             Shares of [Series Preferred Stock] [Common Stock]. 
 2.
Please deliver to the custodian for the selling shareholders a stock certificate representing such              shares. 
 3. The undersigned has instructed the custodian for the selling shareholders to deliver to the Company
$             or, if less, the net proceeds due the undersigned from the sale of shares in the aforesaid public offering. If such net proceeds are less than the purchase price for
such shares, the undersigned agrees to deliver the difference to the Company prior to the Closing. 
  

	
	  

	(Signature)

  

			
	  
	 	
	(Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]